Exelixis, Inc. · EXEL · FY2026 Q3 · Calendar Q4 2026
Exelixis highlights zanzalintinib pipeline after strong Q3
The quarter supports a constructive but conditional view: cabozantinib growth and market-share gains provide an operating base, while zanzalintinib offers the principal expansion opportunity. The thesis still depends on regulatory progress, clinical results, and execution across the pipeline.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about EXEL FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management emphasized zanzalintinib as the leading R&D priority, highlighted Wave 2 pivotal work, introduced XL558 as a new IND candidate, and updated FY2026 assumptions for gross-to-net deductions and taxes.
Guidance delta
Updated FY2026 guidance reflects lower projected gross-to-net deductions and revised tax assumptions; the supplied analysis does not characterize the overall guidance direction.
Key takeaways
- Cabozantinib revenue and market share increased, supporting the current commercial franchise.
- Management identified zanzalintinib as the top R&D priority, with pivotal trials spanning several tumor types.
- The company reported $250 million of share repurchases this quarter and $348 million of remaining authorization.
- XL558 was nominated as a new IND candidate, with filing planned later in 2026.
Management priorities
- Advance zanzalintinib Wave 1 and Wave 2 pivotal trials.
- Prepare for a potential colorectal-cancer zanzalintinib launch following regulatory action.
- Expand the gastrointestinal sales team and community penetration.
- Submit the XL558 IND and continue combination-therapy development.
Follow EXEL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationExelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | — | +9.7% | BrightSpring posts broad Q3 growth while IRA pressure persists |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +1.2% | AbbVie Q3 2026: Guidance Raised as Immunology Drives Growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | — | +9.9% | BrightSpring Q3: Pharmacy Growth Offsets IRA Pressure |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +12.3% | Regeneron: Core Brands Grow as Pipeline Milestones Advance |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
| RMD ResMed Inc. | FY2027 Q1 · Calendar Q4 2026 | +8.2% | -9.1% | ResMed reaffirms FY27 outlook as products and digital health support growth |
Latest beats and misses
Who reports nextBeat on EPS
- WYFY2026 Q3 · October 29, 2026+128.3% EPS+3.0% move
- LNTFY2026 Q3 · October 29, 2026+16.0% EPS+1.4% move
- MTZFY2026 Q3 · October 29, 2026+0.3% EPS+0.8% move
- ERIEFY2026 Q3 · October 29, 2026+2.1% EPS+5.3% move
- IRFY2026 Q3 · October 29, 2026+18.5% EPS+0.2% move
- VLTOFY2026 Q3 · October 29, 2026+8.3% EPS+9.8% move
Get the EXEL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T14:05:08.138958+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-31T00:30:41.543481+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T00:30:41.540788+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.